CA2959841C - Traitement des cancers au moyen d'agents anti-nkg2a - Google Patents

Traitement des cancers au moyen d'agents anti-nkg2a

Info

Publication number
CA2959841C
CA2959841C CA2959841A CA2959841A CA2959841C CA 2959841 C CA2959841 C CA 2959841C CA 2959841 A CA2959841 A CA 2959841A CA 2959841 A CA2959841 A CA 2959841A CA 2959841 C CA2959841 C CA 2959841C
Authority
CA
Canada
Prior art keywords
nkg2a
antibody
hnscc
seq
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2959841A
Other languages
English (en)
Other versions
CA2959841A1 (fr
Inventor
Pascale Andre
Mathieu Blery
Caroline Soulas
Nicolai Wagtmann
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Priority claimed from PCT/EP2015/074581 external-priority patent/WO2016062851A1/fr
Publication of CA2959841A1 publication Critical patent/CA2959841A1/fr
Application granted granted Critical
Publication of CA2959841C publication Critical patent/CA2959841C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne le complexe HLA-E en tant qu'un mécanisme d'échappement tumoral dans le cancer de la tête et du cou. La présente invention concerne des procédés pour le traitement de cancer de la tête et du cou, notamment le complexe HLA-E exprimant le carcinome à cellules squameuses de la tête et du cou, au moyen d'anticorps qui se lient spécifiquement et inhibent le NKG2A humain.
CA2959841A 2014-10-23 2015-10-23 Traitement des cancers au moyen d'agents anti-nkg2a Active CA2959841C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067642P 2014-10-23 2014-10-23
US62/067,642 2014-10-23
PCT/EP2015/074581 WO2016062851A1 (fr) 2014-10-23 2015-10-23 Traitement des cancers au moyen d'agents anti-nkg2a

Publications (2)

Publication Number Publication Date
CA2959841A1 CA2959841A1 (fr) 2016-04-28
CA2959841C true CA2959841C (fr) 2024-09-03

Family

ID=

Similar Documents

Publication Publication Date Title
US11225519B2 (en) Treatment of cancers using anti-NKG2A agents
US11572410B2 (en) Neutralization of inhibitory pathways in lymphocytes
JP7531667B2 (ja) リンパ球における阻害経路の中和
KR20190035863A (ko) 암 치료를 위한 항Siglec-7 항체
EP3193929A1 (fr) Régimes de traitement utilisant des anticorps anti-nkg2a
AU2019233507B2 (en) Treatment of head and neck cancer
CA2959841C (fr) Traitement des cancers au moyen d'agents anti-nkg2a
HK40029948A (en) Treatment of cancers using anti-nkg2a agents
HK40110316A (en) Neutralization of inhibitory pathways in lymphocytes
HK40058058A (en) Neutralization of inhibitory pathways in lymphocytes